JP2023534460A - コンジュゲーション部位を有するt細胞調節性ポリペプチド及びその使用方法 - Google Patents

コンジュゲーション部位を有するt細胞調節性ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP2023534460A
JP2023534460A JP2023502701A JP2023502701A JP2023534460A JP 2023534460 A JP2023534460 A JP 2023534460A JP 2023502701 A JP2023502701 A JP 2023502701A JP 2023502701 A JP2023502701 A JP 2023502701A JP 2023534460 A JP2023534460 A JP 2023534460A
Authority
JP
Japan
Prior art keywords
cell
polypeptide
sequence
mod
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534460A5 (enExample
Inventor
ディー. セイデル ザ サード ロナルド
ジェイ. チャパルロ ロドルフォ
エフ. ロス ジョン
メング ロー チー
スリ アニッシュ
ジェイ. モニズ レイモンド
サグ ガーパンナ
Original Assignee
キュー バイオファーマ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ,インコーポレーテッド filed Critical キュー バイオファーマ,インコーポレーテッド
Publication of JP2023534460A publication Critical patent/JP2023534460A/ja
Publication of JP2023534460A5 publication Critical patent/JP2023534460A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2023502701A 2020-07-14 2021-07-14 コンジュゲーション部位を有するt細胞調節性ポリペプチド及びその使用方法 Pending JP2023534460A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063051472P 2020-07-14 2020-07-14
US63/051,472 2020-07-14
US202063110929P 2020-11-06 2020-11-06
US63/110,929 2020-11-06
US202063120677P 2020-12-02 2020-12-02
US63/120,677 2020-12-02
PCT/US2021/041675 WO2022015880A2 (en) 2020-07-14 2021-07-14 T-cell modulatory polypeptides with conjugation sites and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023534460A true JP2023534460A (ja) 2023-08-09
JP2023534460A5 JP2023534460A5 (enExample) 2024-07-26

Family

ID=79556024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502701A Pending JP2023534460A (ja) 2020-07-14 2021-07-14 コンジュゲーション部位を有するt細胞調節性ポリペプチド及びその使用方法

Country Status (10)

Country Link
US (1) US20230279076A1 (enExample)
EP (1) EP4182465A4 (enExample)
JP (1) JP2023534460A (enExample)
KR (1) KR20230052881A (enExample)
CN (1) CN116437952A (enExample)
AU (1) AU2021309842A1 (enExample)
CA (1) CA3174097A1 (enExample)
IL (1) IL299834A (enExample)
TW (1) TW202216750A (enExample)
WO (1) WO2022015880A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505591B2 (en) * 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
WO2023201234A2 (en) * 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
JP2025515575A (ja) * 2022-04-14 2025-05-20 キュー バイオファーマ, インコーポレイテッド T細胞エンゲージングポリペプチドおよびその使用方法
WO2024206207A1 (en) * 2023-03-24 2024-10-03 Neximmune, Inc. Injectable artificial antigen presenting cells for immune therapy
EP4484441A1 (en) * 2023-06-26 2025-01-01 Eberhard-Karls-Universität Tübingen Mhc-class i derived polypeptide
CN118027176B (zh) * 2024-03-27 2024-12-24 郑春杨 人β2-微球蛋白突变体
WO2025207816A1 (en) * 2024-03-27 2025-10-02 Cue Biopharma, Inc. Treatment of b-cell mediated immune disorders by t-cell mediated depletion of b cells, plasmablasts and plasma cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501900A (ja) * 2012-12-21 2016-01-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質
WO2019126818A1 (en) * 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
WO2020132297A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
EA202090471A1 (ru) * 2017-09-07 2020-06-10 Кью Биофарма, Инк. Модулирующие т-клетки мультимерные полипептиды и способы их применения
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501900A (ja) * 2012-12-21 2016-01-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質
WO2019126818A1 (en) * 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
WO2020132297A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof

Also Published As

Publication number Publication date
CA3174097A1 (en) 2022-01-20
WO2022015880A3 (en) 2022-03-03
KR20230052881A (ko) 2023-04-20
CN116437952A (zh) 2023-07-14
US20230279076A1 (en) 2023-09-07
WO2022015880A2 (en) 2022-01-20
TW202216750A (zh) 2022-05-01
AU2021309842A1 (en) 2023-02-16
IL299834A (en) 2023-03-01
EP4182465A4 (en) 2024-08-07
EP4182465A2 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
JP7762068B2 (ja) 多量体t細胞調節性ポリペプチド及びその使用方法
US20230279076A1 (en) T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
US20250041404A1 (en) T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
US20220017597A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023082126A (ja) 免疫応答を調節するための方法
US20240034770A1 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
JP7481342B2 (ja) 多量体t細胞調節ポリペプチド及びその使用方法
US20240082411A1 (en) T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
US20230201335A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
US20240317815A1 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
US20250041396A1 (en) T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
EA049738B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
CN118401252A (zh) T细胞调节多聚体多肽及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106